Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study

Article summary

Pasithea Therapeutics reported positive clinical data from its ongoing Phase 1 study of PAS-004, a macrocyclic MEK inhibitor, presented at the ESMO Congress 2026.